Exercise News and Research

Latest Exercise News and Research

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Exercise and education program reduces disability and improves physical function after back surgery

Patients who have undergone a single-level lumbar microdiskectomy for lumbar disk herniation experienced significant improvement in physical function following an intensive, progressive physical therapist guided exercise and education program, according to a research report published in the November issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association (APTA).

25 Nov 2009

Third-quarter financial results announced by SemBioSys Genetics

SemBioSys Genetics Inc., specializing in the manufacture of high-value proteins and oils in plant seeds, today announced its third quarter 2009 financial and operational results.

25 Nov 2009

CXCL5 molecule causes insulin resistance and type 2 diabetes in obese people

Many people who are overweight or obese develop insulin resistance and type 2 diabetes at some stage in their lives. A European research team has now discovered that obese people have large amounts of the molecule CXCL5, produced by certain cells in fatty tissue.

25 Nov 2009

Orexigen Therapeutics' committee grants an inducement stock option

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that on November 18, 2009 the Compensation Committee of the Company's Board of Directors granted an inducement stock option to purchase 200,000 shares of common stock to Preston Klassen, M.D., its newly appointed Head of the Global Contrave Program.

24 Nov 2009

DJO's new Moveo XP Rehabilitation Platform granted U.S. patent

DJO Incorporated, a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced that its Chattanooga division was issued U.S. Patent No. 7597656 for Chattanooga’s new Moveo XP Rehabilitation Platform. The Moveo XP is the first product of its kind, allowing patients who are incapable of supporting full body weight to participate in graded weight-bearing activity at an earlier stage in their physical rehabilitation.

24 Nov 2009

'Best New Elliptical' award for LifeSpan EL3000i elliptical trainer

New compact LifeSpan Elliptical Trainers, made by PCE Health and Fitness (www.lifespanfitness.com), were highly rated in annual fitness equipment reviews of best treadmills and elliptical trainers for 2010.

24 Nov 2009

New MEMS sensor may help clinicians distinguish stable and unstable plaque during cardiac emergencies

University of Sourthern California biomedical engineer and cardiologist Tzung "John" Hsiai hopes to develop a new tool to help clinicians distinguish cardiac emergencies requiring immediate surgery from chronic problems manageable with drugs and lifestyle change.

24 Nov 2009

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Merck said today that U.S. District Court Judge John F. Keenan granted summary judgment in Merck's favor in Flemings v. Merck. Flemings is the second of three cases involving FOSAMAX (alendronate sodium) designated by the federal MDL court as a bellwether trial case.

24 Nov 2009

Physical exercise - one of the most effective methods of preventing disease

Physical exercise is one of the most effective methods of preventing disease. The current issue of Deutsches -rzteblatt International is devoted to this important topic.

24 Nov 2009

Seattle Genetics and Agensys expand ADC collaboration

Seattle Genetics, Inc. (Nasdaq: SGEN) and Agensys, Inc., an affiliate of Astellas, announced today an expansion of the companies’ antibody-drug conjugate (ADC) collaboration. Under the amended agreement, Agensys will pay a $12 million fee for exclusive rights to ADC licenses against additional antigen targets. Seattle Genetics also receives an option to co-develop another ADC at the time of investigational new drug (IND) submission.

24 Nov 2009

Researchers find causes for patellofemoral pain syndrome

From professional athletes to weekend warriors, the condition known as "runner's knee" is a painful and potentially debilitating injury suffered by millions of people - although until now, it has been unclear just what causes it.

24 Nov 2009

Salix Pharmaceuticals raises $128.2 million for business development activities

Salix Pharmaceuticals, Ltd., a specialty pharmaceutical company, today announced it has closed its previously announced public offering of 5,500,000 shares of its common stock at a price of $21.00 per share.

24 Nov 2009

New computational tool may aid surgeons plan for life-saving pediatric operation

A team of researchers at the University of California, San Diego and Stanford University has developed a way to simulate blood flow on the computer to optimize surgical designs. It is the basis of a new tool that may help surgeons plan for a life-saving operation called the "Fontan" surgery, which is performed on babies born with severe congenital heart defects.

24 Nov 2009

Study: Men who do moderate-to-heavy intensity exercise are less likely to have stroke

Men who regularly take part in moderate-to-heavy intensity exercise such as jogging, tennis or swimming may be less likely to have a stroke than people who get no exercise or only light exercise, such as walking, golfing, or bowling, according to a study published in the November 24, 2009, print issue of Neurology ®, the medical journal of the American Academy of Neurology.

24 Nov 2009

Walgreens re-launches its website with expanded shopping tools and services

Walgreens, the nation’s largest drugstore chain and a leading destination for health and wellness services, today announced the re-launch of Walgreens.com (www.walgreens.com), offering users a variety of new healthy living and product resources, along with expanded yet simplified shopping tools and services.

23 Nov 2009

Phase IIb/III clinical trial results of CINQUIL for pediatric EoE announced

Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.

23 Nov 2009

100th patient enrolled in Atrium Medical's iCAST Atrium Registry Ultrasound Study

Atrium Medical Corporation announced that the 100th patient was enrolled in the iCAST™ Atrium Registry Ultrasound Study (iCARUS). The iCARUS study is a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST™ Balloon Expandable Covered Stent in patients with occlusive disease in the iliac artery.

23 Nov 2009

Foods rich in antioxidant substances could delay the onset of Alzheimer's disease

Universitat Autònoma de Barcelona (UAB) researchers have confirmed that a diet rich in polyphenols and polyunsaturated fatty acids, patented as an LMN diet, helps boost the production of the brain's stem cells -neurogenesis- and strengthens their differentiation in different types of neuron cells.

23 Nov 2009

Obesity: A major contributor to the development of Type 2 diabetes

"Many Americans have a very limited understanding of the basic facts about diabetes, as well as the serious consequences for health that accompany the disease," commented Sue McLaughlin, RD, CDE, President, Health Care & Education, American Diabetes Association, in a media alert. She blames the problem on a combination of factors including denial of the disease and promotion of inaccurate information or myths surrounding diabetes.

21 Nov 2009